Alnylam Achieves Alignment with FDA on Accelerated Development Path for Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
Go back to Alnylam Achieves Alignment with FDA on Accelerated Development Path for Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 244.32 +4.76 (1.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $239.56 | 52 Week High | $109.10 | |||
| Open | $240.37 | 52 Week Low | $31.38 | |||
| Day High | $247.10 | P/E | N/A | |||
| Day Low | $237.97 | EPS | $-1.45 | |||
| Volume | 1,152,873 | |||||
